Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice

Journal of Bone and Mineral Metabolism

Volumn 29, Issue 2, 2011, Pages 141-148

  Yao, Gang Qing ^a   Wu, Jian Jun ^a   Troiano, Nancy ^a   Insogna, Karl ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dkk1; Osteoblasts; Osteoclasts; PTH; Wnt

Indexed keywords

DICKKOPF 1 PROTEIN; MESSENGER RNA; PARATHYROID HORMONE[1-34]; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DICKKOPF 1 TRANSGENE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOBLAST NUMBER PER TOTAL AREA; OSTEOBLAST SURFACE; OSTEOCLAST; OSTEOID VOLUME; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID HORMONE SYNTHESIS; TIBIA; TRANSGENE; WILD TYPE;

ANIMALS; BONE AND BONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; PARATHYROID HORMONE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960030492     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-010-0202-3     Document Type: Article

References (26)

1. Williams BO, Insogna KL (2009) Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res 24:171
2. Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469-7481 (Pubitemid 44885746)
3. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521 (Pubitemid 34755690)
4. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494 (Pubitemid 38010074)
5. Qiang Y-W, Barlogie B, Rudikoff S, Shaughnessy JD Jr (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone (NY) 42:669-680
6. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425-436
7. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (NY) 39:754-766 (Pubitemid 44311706)
8. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière Ba, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934
9. MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV (2007) Bone mass is inversely proportional to Dkk1 levels in mice. Bone (NY) 41:331-339 (Pubitemid 47199155)
10. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95:1178-1190 (Pubitemid 41420125)
11. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X (2008) Parathyroid hormone signaling through lowdensity lipoprotein-related protein 6. Genes Dev 22:2968-2979
12. Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K (2006) Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147:2583-2590
13. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH (2006) The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698-23711 (Pubitemid 44274145)
14. Iwaniec UT, Wronski TJ, Liu J, Rivera MF, Arzaga RR, Hansen G, Brommage R (2007) PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 22:394-402 (Pubitemid 46797122)
15. Wan M, Yang C, Yuan H, Wu X, Lu C, Chang C, Cao X (2007) Parathyroid hormone activates beta-catenin signaling through LRP5/6. J Bone Miner Res 22:S83
16. Yao GQ, Wu JJ, Sun BH, Troiano N, Mitnick MA, Insogna K (2003) The cell surface form of colony-stimulating factor-1 is biologically active in bone in vivo. Endocrinology 144:3677-3682 (Pubitemid 36904447)
17. Yao GQ, Sun BH, Weir EC, Insogna KL (2002) A role for cellsurface CSF-1 in osteoblast-mediated osteoclastogenesis. Calcif Tissue Int 70:339-346 (Pubitemid 36935450)
18. Weir EC, Philbrick WM, Amling M, Neff LA, Baron R, Broadus AE (1996) Targeted overexpression of parathyroid hormonerelated peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci USA 93:10240-10245 (Pubitemid 26314606)
19. Baron R, Vignery A, Neff L, Silvergate A, Santa Maria A (1983) Bone histomorphometry. In: Recker R (ed) Techniques and interpretation. CRC Press, Boca Raton, pp 31-32
20. Insogna KL, Stewart AF, Vignery AM, Weir EC, Namnum PA, Baron RE, Kirkwood JM, Deftos LM, Broadus AE (1984) Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology 114:888-896 (Pubitemid 14166097)
21. Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K (2005) The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146:1983-1990 (Pubitemid 40396908)
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
23. Semenov MV, Zhang X, He X (2008) DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation. J Biol Chem 283:21427-21432
24. Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT (2005) Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem 95:403-418 (Pubitemid 41420208)
25. Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189
26. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837 (see comment)